Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Immunomedics Reveals Study Results For Radioimmunotherapy Of Colorectal Cancer

RELATED NEWS
Trade IMMU now with 

Biopharmaceutical company Immunomedics Ic (IMMU: Quote) Monday revealed that colorectal cancer can be safely, specifically and rapidly targeted with TF2 bispecific antibody and a radiolabeled peptide, with limited toxicity to the patient.

The company stated that TF2 is a bi-specific antibody created using the patented Dock-and-Lock conjugation technology. In addition to targeting the carcinoembryonic antigen expressed by many human cancers, TF2 has been engineered to recognize a small peptide that carries radioactivity. This allows the injection of radioactivity to be separated from the administration of the tumor-targeting bispecific antibody, a concept known as pretargeting.

The company further stated that the study results revealed that pretargeting has the potential advantage of delivering increased radiation dose levels selectively to the tumors while minimizing the body's exposure to radiation's harmful side effects.

Click here to receive FREE breaking news email alerts for Immunomedics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Home improvement and building products company Masco Corp. said Monday after the markets closed that its second quarter profit jumped 78% from last year, as revenue increased and margins improved amid strong performance of its Plumbing Products, Installation and Other Services and Decorative Architectural Products segments. American Financial Group Inc. (AFG) Monday reported second-quarter net earnings of $106 million or $1.15 per share, compared to $110 million or $1.20 per share last year. Core net operating earnings were $99 million or $1.07 per share, compared to $87 million or $0.96 per share last year. Total... Stocks showed a significant recovery over the course of the trading day on Monday after coming under pressure in early trading. The markets eventually ended the session roughly flat following the mixed performance that was seen last week.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.